<- Go Home

Moderna, Inc.

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Market Cap

$22.1B

Volume

10.8M

Cash and Equivalents

$2.6B

EBITDA

-$2.9B

Tax Rate Collected

N/A

Tax Rate Ratio

N/A

Gross Profit

-$2.1B

Profit Margin

105.76%

52 Week High

$59.55

52 Week Low

$22.28

Dividend

N/A

Price / Book Value

2.55

Price / Earnings

-7.72

Price / Tangible Book Value

2.58

Enterprise Value

$15.3B

Enterprise Value / EBITDA

-5.56

Operating Income

-$3.1B

Return on Equity

28.87%

Return on Assets

-14.51

Cash and Short Term Investments

$5.8B

Debt

$1.3B

Equity

$8.7B

Revenue

$1.9B

Unlevered FCF

-$1.3B

Sector

Biotechnology

Category

N/A

Hedge Funds that own this stock

PREMIUM

Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).

Upgrade to Yellowbrick Premium

Yellowbrick Portfolios that own this stock

PREMIUM

Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).

Upgrade to Yellowbrick Premium

Company Stock Pitches